Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH - Kimura, Y; Hyogo, H; Yamagishi, S (J Gastroenterol, 2010)